Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.
The MDGS news page on Stock Titan provides an organized view of announcements and disclosures related to the company historically associated with Medigus and, in more recent communications, with Xylo Technologies Ltd. Medigus is described as a medical device company in surgical and medical instrument manufacturing, focused on endoscopic systems for GERD treatment, while Xylo is presented in news releases as a technologies company engaged in advanced medical solutions, digital commerce, and electric vehicle markets through various affiliates.
News items connected to this lineage describe Xylo Technologies as based in Israel and traded on the Nasdaq Capital Market under the symbol XYLO. These releases highlight affiliations in advanced medical solutions via Polyrizon Ltd., in digital commerce via Gix Internet Ltd. and Eventer Technologies Ltd., and in electric vehicle technologies through Charging Robotics, Inc. and Revoltz Ltd. Other affiliations mentioned include ParaZero Technologies Ltd. and Zig Miami 54 LLC.
On this page, readers can review company-related news that may cover topics such as developments in advanced medical solutions, updates from affiliated digital advertising and digital commerce businesses, progress in electric vehicle wireless charging systems, micro-mobility vehicles for last-mile logistics, and drone safety technologies. Each article reflects how the broader group of affiliated companies is described as pursuing technology-based growth partnerships.
Investors and followers of MDGS can use this news feed to trace how the focus described for Medigus as a medical device manufacturer connects with later descriptions of Xylo Technologies’ wider technology portfolio. Regularly reviewing these items can help users understand how the company’s affiliations in medical, digital, and electric vehicle-related fields are presented in public communications.
Medigus Ltd. (NASDAQ: MDGS) announced new agreements with Polyrizon Ltd. on July 17, 2020. Medigus secured an exclusive global license to sell Polyrizon's innovative Biogel for COVID-19 protection, with a four-year term starting upon FDA approval. The investment agreement involves $10,000 and a $94,000 loan to Polyrizon, yielding Medigus a 19.9% stake. Additionally, Medigus has an option to invest $1,000,000 for a controlling 51% interest. Polyrizon's products aim to mitigate the risks from COVID-19 and airborne allergens.
Medigus Ltd. (NASDAQ: MDGS) has increased its stake in ScoutCam to 50.1% by converting $381,136 in credit into equity. This move comes after a recent $2 million investment in ScoutCam by entrepreneur Mori Arkin. CEO Liron Carmel emphasized the company's belief in ScoutCam's potential, citing new customer engagements and strengthened intellectual property. ScoutCam specializes in customized visual solutions across various sectors, including medical, aerospace, and industrial fields.
Medigus Ltd. (NASDAQ: MDGS) announced that its subsidiary, ScoutCam Ltd., has received a patent in Canada for its innovative endoscope irrigation technology. This patent, already approved in the U.S., EU, and Japan, underscores ScoutCam's ability to create compact and durable micro-cameras suitable for various applications in medical and industrial fields. The new technology integrates irrigation within the endoscope, allowing for a smaller device diameter, enhancing visibility, and streamlining procedures. ScoutCam's camera systems have proven robust in diverse conditions, further emphasizing their market leadership.
Medigus Ltd. has successfully completed an underwritten public offering of 3,333,334 American Depositary Shares (ADSs), priced at $1.50 each, generating approximately $5 million in gross proceeds. Additionally, pre-funded ADS purchase warrants were also offered at $1.499 each. The proceeds will be utilized for working capital and general corporate purposes. The offering was managed by ThinkEquity, a division of Fordham Financial Management. A registration statement regarding the ADSs has been filed with the SEC.
Medigus Ltd. (NASDAQ: MDGS) announced its subsidiary, ScoutCam Inc., has successfully integrated its wireless micro ScoutCam into medical endoscopes, introducing what may be the first operating room-ready wireless endoscope. Approved by the FDA, this device marks a significant advancement in endoscopy, featuring a single-use micro camera that is significantly smaller than traditional options. This innovation aims to enhance efficiency in endoscopic surgeries, particularly in treating conditions like carpal tunnel syndrome, impacting millions of Americans.
Medigus Ltd. (Nasdaq, TASE: MDGS) has announced a public offering of 3,333,334 American Depositary Shares (ADSs) at $1.50 each and Pre-Funded Warrants at $1.499 each, expected to raise approximately $5 million before expenses. The offering will close on May 22, 2020, pending standard conditions. Proceeds are designated for working capital and general corporate purposes. This follows a shelf registration with the SEC, indicating readiness for future capital raises.
Medigus Ltd. (NASDAQ:MDGS) announced plans for an underwritten public offering of American Depositary Shares and pre-funded warrants, subject to market conditions. The proceeds will be used for working capital and general corporate purposes. A shelf registration statement has been filed with the SEC, although specifics on the offering size and terms remain uncertain. ThinkEquity is the sole book-running manager. Forward-looking statements caution that completion of the offering is not guaranteed and may be influenced by various risks and uncertainties.
Medigus Ltd. (NASDAQ:MDGS) has signed a binding letter of intent with Polyrizon Ltd. for a collaboration focused on developing biological gels aimed at protecting against COVID-19. Polyrizon has filed a US patent application for its innovative formulations designed to prevent virus interaction with mucosal membranes. The agreement provides Medigus with exclusive marketing rights for four years and involves an initial investment granting Medigus 20% of Polyrizon’s capital, with an option to increase to 30%. The joint effort seeks to commercialize a topical Biogel solution for COVID-19 protection.
Summary not available.